- The comprehensive genomic profiling in early-stage (T1-2N0-1M0) breast cancerChen, Bo; Li, Yingzi; Zhang, Yuchen; Zhang, Guochun; Du, Haiwei; Sun, Dailin; Li, Junjun; Liao, NingAnnual Meeting of the American-Association-for-Cancer-Research (AACR), New Orleans, LA, 2022-04-08 To 2022-04-13.
- Analysis of Circulating Tumor DNA (ctDNA) in Triple Negative and HER2 Positive Breast Cancer Patients throughout Neoadjuvant Chemotherapy. A Proof of Concept StudyCiriaco, Nikaoly; Zamora, Esther; Escriva de Romani, Santiago; Somoza, Rosa; Hernandez-Losa, Javier; Ramon Y Cajal, Santiago; Peg, Vicente; Espinosa-Bravo, Martin109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), Los Angeles, CA, 2020-02-29 To 2020-03-05.
- HER2 Evaluation and Its Impact on Breast Cancer Treatment DecisionsK.A.B. Goddard; S. Weinmann; K. Richert-Boe; C. Chen; J. Bulkley; C. WaxPublic Health Genomics, 2012, 15(1): 1-10.
会议论文
Multi-omic subtyping and molecular determinants of neoadjuvant therapeutic regimen for locally advanced HER2-positive and triple-negative breast cancer: Implications of novel therapy.
9阅读
